Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma

  • End date
    Jan 31, 2025
  • participants needed
  • sponsor
    Academic and Community Cancer Research United
Updated on 15 July 2022


This phase I trial studies the side effects and best dose of gemcitabine and cisplatin when given together with ivosidenib or pemigatinib in treating patients with cholangiocarcinoma that cannot be removed with surgery (unresectable) or has spread to other places in the body (metastatic). Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ivosidenib and pemigatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gemcitabine and cisplatin with ivosidenib or pemigatinib may work better in treating patients with cholangiocarcinoma compared to gemcitabine and cisplatin alone.



I. To evaluate the safety, tolerability, maximum tolerated dose (MTD) and/or recommended phase 2 dose, gemcitabine and cisplatin in combination with either ivosidenib or pemigatinib.


I. To evaluate median and progression free survival (PFS) for 6 months per investigator assessment.

II. To evaluate the rate of overall survival (OS) in patients treated with gemcitabine and cisplatin in combination with either ivosidenib or pemigatinib.

III. To describe the overall toxicity and adverse events profile associated with gemcitabine and cisplatin in combination with either ivosidenib or pemigatinib.

IV. To determine the best response profile per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria in patients treated with gemcitabine and cisplatin in combination with either ivosidenib or pemigatinib.


I. To measure plasma 2-hydroxglutarate (2-HG) levels =< 21 days prior to registration and at cycle 4 day 1 (+/- 2 days).

OUTLINE: This is a dose de-escalation study. Patients are assigned to 1 of 2 arms.

ARM A (IDH1 GENE MUTATION): Patients receive ivosidenib orally (PO) on days 1-21, cisplatin intravenously (IV) on days 1 and 8, and gemcitabine IV on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

ARM B (FGFR2 GENE ALTERATION): Patients receive pemigatinib PO on days 1-21, cisplatin IV on days 1 and 8, and gemcitabine IV on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days and then every 6 months for up to 3 years.

Condition Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Unresectable Cholangiocarcinoma
Treatment cisplatin, Gemcitabine, Ivosidenib, pemigatinib
Clinical Study IdentifierNCT04088188
SponsorAcademic and Community Cancer Research United
Last Modified on15 July 2022


Yes No Not Sure

Inclusion Criteria

Histopathological diagnosis (fresh) or banked tumor biopsy sample collected within the last 3 years from the registration date consistent with nonresectable or metastatic cholangiocarcinoma and are not eligible for curative resection, transplantation, or ablative therapies
Documented disease without any evidence of progression following at least 3 cycles of standard-of-care chemotherapy including gemcitabine and cisplatin as part of first-line systemic therapy; NOTE: Only patients receiving standard-of-care chemotherapy including gemcitabine and cisplatin as first-line therapy for unresectable or metastatic cholangiocarcinoma will be permitted to enroll in this trial. Prior systemic adjuvant chemotherapy is allowed as long as there was no evidence of recurrence within 6 months of completing the adjuvant therapy
Molecular testing result from Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory (using fresh tumor biopsy or most recent banked tumor tissue available) confirming that the tumor tissue has at least one of the following
IDH1 gene mutation (R132C/L/G/H/S mutation)
FGFR2 gene alteration
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
Life expectancy >= 3 months
At least one evaluable and measurable lesion by RECIST criteria prior to beginning chemotherapy with gemcitabine and cisplatin
NOTE: Subjects who have received prior local therapy (including but not limited to embolization, chemoembolization, radiofrequency ablation, hepatic arterial infusion, or radiation therapy) are eligible provided measurable disease falls outside of the treatment
Recovered from toxicities associated with prior anticancer therapy to baseline unless
Absolute neutrophil count >= 1,500/mm^3 (obtained =< 21 days prior to registration)
stabilized under medical management
Platelet count >= 100,000/mm^3 (obtained =< 21 days prior to registration)
Hemoglobin >= 8 g/dL (obtained =< 21 days prior to registration)
Serum total bilirubin =< 2.0 x upper limit of normal (ULN), unless considered due to Gilbert's disease. If Gilbert's disease or disease involving liver, serum total bilirubin =< 2.5 x ULN (obtained =< 21 days prior to registration)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5.0 x ULN in the presence of liver metastases (obtained =< 21 days prior to registration)
Serum creatinine < 1.5 x ULN OR creatinine clearance >= 50 mL/min based on the Cockcroft-Gault glomerular filtration rate (GFR) estimation (obtained =< 21 days prior to registration)
Serum phosphate =< institutional ULN and potassium within institutional normal range for Arm B only (obtained =< 21 days prior to registration)
NOTE: Supplemental potassium may be used to correct potassium prior to registration
NOTE: Females of reproductive potential are defined as sexually mature women who have not undergone a hysterectomy, bilateral oophorectomy, or tubal occlusion or who have not been naturally postmenopausal (i.e., who have not menstruated) for >= 24 consecutive months (i.e., have not had menses at any time in the preceding 24 consecutive months)
Negative serum pregnancy test done =< 7 days prior to registration for women of
childbearing potential only
NOTE: Effective forms of contraception are defined as hormonal oral contraceptives, injectables, patches, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal ligation, condoms with spermicide, or male partner sterilization
Able to understand and willing to sign the informed consent form
Women of reproductive potential and fertile men must agree to use 2 effective forms of
NOTE: A legally authorized representative may consent on behalf of a subject who is otherwise unable to provide informed consent if acceptable to and approved by the site's Institutional Review Board (IRB)/Independent Ethics Committee (IEC)
contraception (including at least 1 barrier form) from the time of giving
informed consent throughout the study and for 90 days (both females and males)
Willing to provide blood samples for correlative research purposes
following the last dose of study drug
Able to comply with scheduled visits, treatment plans, procedures, and laboratory
tests, including serial peripheral blood sampling during the study

Exclusion Criteria

Prior therapy with either an IDH inhibitor or selective FGFR inhibitor
IDH inhibitors: ivosidenib, FT-2012, etc
FGFR inhibitors: pemigatinib, BGJ-398, TAS-120, ARQ 087, or derazantinib, etc
Known toxicity to standard-of-care chemotherapy including gemcitabine and cisplatin requiring cessation of this therapy
Received radiotherapy to metastatic sites of disease =< 2 weeks prior to registration
Underwent hepatic radiation, chemoembolization, or radiofrequency ablation =< 4 weeks prior to registration
Known symptomatic brain metastases requiring steroids
NOTE: Subjects with previously diagnosed brain metastases are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to study entry, have discontinued corticosteroid treatment for these metastases for at least 4 weeks and have radiographically stable disease for at least 3 months prior to registration
NOTE: Up to 10 mg per day of prednisone equivalent will be allowed
Progressive disease as best response on current standard-of-care chemotherapy
Other active malignancy =< 5 years prior to registration. EXCEPTIONS
including gemcitabine and cisplatin
Non- melanoma skin cancer unless stage 1a or carcinoma-in-situ of the cervix
Breast cancer with ongoing hormone therapy being administered as adjuvant therapy
NOTE: If there is a history or prior malignancy, they must not be receiving other specific treatment
Any of the following because this study involves investigational agents whose genotoxic, mutagenic, and teratogenic effects on the developing fetus and newborn are
Pregnant women
Nursing women
Men or women of childbearing potential who are unwilling to employ adequate contraception
Arm B: Use of strong CYP3A4 inducers or inhibitors or moderate CYP3A4 inducers
Major surgery =< 4 weeks prior to registration or have not recovered from post-surgery
NOTE: Study principal investigator (PI) approval is needed if continued use of CYP3A4 inducers or inhibitors. Approval can be obtained via email (documentation of approval/eligibility needed)
For Arm B only: Current evidence of clinically significant corneal (including but not limited to bullous/band keratopathy, corneal abrasion, inflammation/ulceration, and keratoconjunctivitis) or retinal disorder (including but not limited to central serous retinopathy, macular/retinal degeneration, diabetic retinopathy, retinal detachment) as confirmed by ophthalmologic examination
Known history and/or current evidence of ectopic mineralization/ calcification, including but not limited to soft tissue, kidneys, intestine, myocardia, or lung, excepting calcified lymph nodes and asymptomatic arterial or cartilage/tendon calcification for Arm B only
Known history of hypovitaminosis D requiring supraphysiologic doses to replenish the deficiency for Arm B only
NOTE: Subjects receiving vitamin D food supplements are allowed
NOTE: At the discretion of the investigator, subjects with tumor fever may be enrolled
Arm A: Use of strong CYP3A4 inducers or strong or moderate CYP3A4 inhibitors. In
Any known hypersensitivity to any of the components of ivosidenib or pemigatinib
addition, sensitive CYP3A4 substrate medications with a narrow therapeutic
Significant, active cardiac disease =< 6 months prior to registration, including
window, unless they can be transferred to other medications =< 4 days or 5
New York Heart Association (NYHA) class III or IV congestive heart failure
half-lives (whichever is shorter) prior to registration
Myocardial infarction
Unstable angina
Note: Bundle branch block and prolonged QTcF interval are permitted with approval of the medical monitor
Note: If equivalent medication is not available, QTcF should be closely monitored
Active infection requiring systemic anti-infective therapy or with an unexplained
fever > 38.5 degrees Celsius (C) =< 7 days of registration
NOTE: Subjects with a sustained viral response to HCV or immunity to prior HBV infection will be permitted. Subjects with chronic HBV that is adequately suppressed per institutional practice will be permitted
NOTE: HBV, HCV, and/or HIV testing is not required prior to trial registration
Inability or unwillingness to swallow ivosidenib or pemigatinib or have significant gastrointestinal (GI) disorder(s) that could interfere with absorption, metabolism, or excretion
NOTE: Gastroesophageal reflux disease under medical treatment is allowed (assuming no drug interaction potential)
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Have a heart-rate corrected QT interval (using Fridericia's formula) (QTcF) >= 450
msec or other factors that increase the risk of QT prolongation or arrhythmic
events (e.g., heart failure, hypokalemia, family history of long QT interval
Taking medications that are known to prolong the QT interval, unless they can be
transferred to other medications >= 5 half-lives prior to registration or
unless the medications can be properly monitored during the study
Known active hepatitis B (hepatitis B virus [HBV]) or hepatitis C (hepatitis C virus
[HCV]) infections, known positive human immunodeficiency virus (HIV) antibody
results, or acquired immunodeficiency syndrome (AIDS) related illness
Any other acute or chronic medical or psychiatric condition, including recent (=< 12
months of registration) or active suicidal ideation or behavior, or a
laboratory abnormality that may increase the risk associated with study
participation or investigational product administration or may interfere with
the interpretation of study results and, in the judgment of the investigator
would make the subject inappropriate for entry into this study
Have been committed to an institution by virtue of an order issued either by the
judicial or administrative authorities
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note